JPRN-jRCTs031180202进行中（未招募）3 期
JCOG1109: A randomized controlled phase III comparing CF versus DCF versus CF-RT as neoadjuvant treatment for locally advanced esophageal cancer - NExT study
Kato Ken0 个研究点目标入组 600 人开始时间: 2019年3月7日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 600
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 75age old（—）
- 性别
- All
入选标准
- •1) Histologically proven squamous cell carcinoma, adenosquamous carcinoma, or basaloid cell carcinoma by endoscopic biopsy from esophageal primary tumor
- •2) All lesion located in the thoracic esophagus (the 7th edition of the UICC TNM classification)
- •3) Clinical stage IB, II, III (excluding T4) based on the 7th edition of the UICC TNM classification
- •4) Aged 20 to 75 years old
- •5) ECOG performance status of 0 or 1
- •6) Measurable lesions not required
- •7) No prior therapy against esophageal cancer except for the following cases
- •a) Complete resection by EMR/ESD (diagnosed as pT1a-EP (M1) or pT1a-LPM (M2) tumors)
- •b) Complete resection by EMR/ESD (diagnosed as pT1a-MM (M3) tumor without lymphovascular invasion)
- •8) No prior chemotherapy, radiotherapy or hormonal therapy against any cancers except for hormonal therapy for prostate cancer with more than 5 years of disease-free interval
- •9) Adequate organ functions
- •10) R0 esophagectomy is judged as possible by open (or laparoscopic) thoracotomy and laparotomy
- •11) Written informed consent
排除标准
- •1) Simultaneous or metachronous (within 5 years) double cancers, except for intramucosal tumor curatively resected by local therapy
- •2) Active infection requiring systemic therapy
- •3) Positive HBs antigen, HCV antibody or HIV antibody
- •4) Pregnant or lactating women or women of childbearing potential
- •5) Psychiatric disease or symptom
- •6) Patients requiring systemic steroids medication (internal or intravenous use)
- •7) Requiring continuous administration of flucytosine, phenytoin or warfarin potassium
- •8) Iodine hypersensitivity
- •9) Hypersensitivity for docetaxel, cisplatin or polysorbate 80 containing drug
- •10) Diabetes mellitus with HbA1c of 6.5% (value of Japan Diabetes Society (JDS)), 6.9% (value of National Glycohemoglobin Standardization Program (NGSP))or higher
- •11) Severe emphysema or pulmonary fibrosis detected by lung function test or CT
- •12) Poorly controlled hypertension
- •13) Unstable angina (onset or worse heart attack of angina within 3 weeks), or with a history of myocardial infarction within 6 months.
研究者
相似试验
招募中
3 期
JCOG2011: A randomized controlled phase III trial for confirming superiority of local radiotherapy added to anti-androgen therapy for prostate cancer patients with high volume metastasis sensitive to hormone therapyhigh volume metastatic prostate cancerJPRN-jRCT1031220676KAMOTO Toshiyuki440
进行中（未招募）
3 期
JCOG1314: A randomized controlled phase III study comparing docetaxel, CDDP and 5-FU with CDDP and 5-FU in patients with metastatic or recurrent esophageal canceresophageal cancerJPRN-jRCTs031180143TSUBOSA Yasuhiro240
招募中
3 期
JCOG1904: A randomized controlled phase III trial of comparing local field with additional prophylactic irradiation in chemoradiotherapy for clinical-T1bN0M0 esophageal canceresophageal cancerJPRN-jRCTs031200067TSUSHIMA Takahiro176
招募中
3 期
JCOG1801: A phase III randomized controlled trial comparing surgery plus adjuvant chemotherapy with preoperative chemoradiotherapy followed by surgery plus adjuvant chemotherapy for locally recurrent rectal cancerresectable locally recurrent rectal cancerJPRN-jRCTs031190076Ito Masaaki110
招募中
3 期
JCOG1905: A randomized controlled phase III trial on continued or paused PD-1 pathway blockade for patients with advanced renal cell carcinomaadvanced renal cell carcinomaJPRN-jRCT1031200071MATSUMOTO Takashi250